Melanoma
Introgen's INGN 241 Product Potentially Useful Gene Therapy
Published in Gene Therapy Weekly, March 15th, 2001
INGN 241 is currently in Phase I clinical development for the treatment of solid tumors.
Elizabeth Grimm, PhD, Ashbel Smith Professor in the Departments of Tumor Biology and Surgical Oncology at The University of Texas M.D. Anderson Cancer Center, and principal investigator of the study, presented these data at the Fifth World Conference on Melanoma, sponsored by the World Health Organization.
The preclinical study showed that INGN 241 caused growth arrest and...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2001-03-15)
More Articles from Gene Therapy Weekly
- Cancer Gene Therapy
Can Simply Swallowing A Gene Actually Treat And Prevent Cancer? - Congestive Heart Failure
Researchers Reverse Damage With Gene Therapy - Cancer Gene Therapy
One-Step Approach For Suicide Vector Kills Tumors - Pancreatic Cancer
Monoclonal Antibodies Deliver Therapy To Targeted Tumors - Anti-Angiogenesis
Protein Licensed As Possible Gene Therapy Candidate To Prevent Blindness - Antisense Technology
Peptide Nucleic Acids Inhibit Gene Expression - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
